title: Azelastine does not adversely affect aerobic performance.
abstract: BACKGROUND
  The effect of the treatment of allergic rhinitis with azelastine on physiological indicators of aerobic performance such as VO2 max and ventilatory threshold (VT) were evaluated. The clinical efficacy of azelastine was also established.
  
  
  METHODS
  
  
  
  METHODS
  fifteen physically active males with allergic rhinitis or rhinoconjunctivitis were selected as subjects (experimental group, EXP). Fifteen physically active, healthy subjects served as controls. Subjects performed a maximal incremental exercise test on a bicycle ergometer (ramp protocol) before and after a 5-day treatment period. During the 5 days, EXP group subjects were treated with azelastine (intranasal dose of 0.56 mg/day). The following variables were recorded before and after treatment: power output (W), HR (beats.min-1), VO2 (ml.kg-1.min-1), minute ventilation (VE, in 1.min-1), and oxygen pulse (VO2.HR-1, in ml.beat -1). Blood lactate concentrations (mmol.l-1) were also determined using capillary blood samples (25 microliters).
  
  
  RESULTS
  No significant difference was found between pre- and post-trial variables in control subjects. However, peak HR values were lower in EXP subjects after treatment with azelastine (190 +/- 6 beats.min-1 pre-treatment vs 186 +/- 56 beats.min-1 post-treatment; p < 0.05). In addition, VE values at the exercise intensity corresponding to VT were higher in EXP after treatment (54.7 +/- 12.8 l.min-1 pre-treatment vs 60.2 +/- 14.6 l.min-1 post-treatment, p < 0.05).
  
  
  CONCLUSIONS
  These findings suggest that the intranasal administration of azelastine used for the treatment of allergic symptoms of the upper respiratory tract in physically active subjects, does not seem to adversely affect maximal aerobic capacity or submaximal aerobic performance.
authors.affiliation: Escuela de Enfermería, Facultad de Medicina, Universidad Complutense, Madrid, Spain.
authors.forename: J L
authors.initials: JL
authors.lastname: Chicharro
authors.forename: A
authors.initials: A
authors.lastname: Lucía
authors.forename: A F
authors.initials: AF
authors.lastname: Vaquero
authors.forename: M
authors.initials: M
authors.lastname: Pérez
mesh_terms: D000281:Administration, Intranasal; D000293:Adolescent; D000328:Adult; D015308:Anaerobic Threshold / Q000187:drug effects; D018926:Anti-Allergic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003233:Conjunctivitis, Allergic / Q000188:drug therapy; D005080:Exercise Test; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007773:Lactates / Q000097:blood; D008297:Male; D010100:Oxygen / Q000097:blood; D010101:Oxygen Consumption / Q000187:drug effects*; D010793:Phthalazines / Q000008:administration & dosage / Q000627:therapeutic use*; D005082:Physical Exertion / Q000502:physiology*; D012119:Respiration / Q000187:drug effects; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy
chemical_list: D018926:Anti-Allergic Agents; D007773:Lactates; D010793:Phthalazines; D010100:Oxygen; C020976:azelastine